Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]

Abstract

Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D. Clinicoecon Outcomes Res. 2017;9:173–179.  On page 174, Methods section, 1st paragraph, the last sentence reads “The percentage of patients eligible for dual therapy (ATV+r+3TC) was derived from the Atlas-M trial at 48 weeks,20 in which patients were eligible to simplification if aged >17 years, receiving for at least 6 months ATV+r+2 NRTI, with “at least two HIV-RNA levels <50 copies/mL on two consecutive determinations at least 3 months apart,” for at least 6 months with a CD4 cell count >200 cells/mm3, no history of AIDS-related events in the year before enrollment.”. The correct sentence is “The percentage of patients eligible for dual therapy (ATV+r+3TC) was derived from the Atlas-M trial at 48 weeks,20 in which patients were eligible to simplification if aged ≥18 years, receiving for at least 6 months ATV+r+2 NRTI, with “at least two HIV-RNA levels <50 copies/mL on two consecutive determinations at least 3 months apart,” for at least 6 months with a CD4 cell count >200 cells/mm3, no history of AIDS-related events in the year before enrollment.”.Read the original article